Literature DB >> 9125274

1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.

D Amin1, S A Cornell, M H Perrone, G E Bilder.   

Abstract

Squalene synthase, the first committed enzyme for sterol synthesis, converts farnesyl pyrophosphate to squalene with presqualene pyrophosphate as an intermediate. It was discovered that BM 21.0955 (1-hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphon ic acid), in development for the treatment of bone disorders, inhibited rat liver microsomal squalene synthase (K(i) = nmol/l). BM 21.0955 also inhibited sterol biosynthesis from mevalonate (IC50 = 42 nmol/l), and cholesterol biosynthesis in J774 cells (IC50 = mumol/l). Structural modifications on this molecule to make it more lipophilic may result in a new class of cholesterol-lowering agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9125274

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis.

Authors:  Christian Walter; Knut A Grötz; Martin Kunkel; Bilal Al-Nawas
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

Review 2.  Bisphosphonates pathway.

Authors:  Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2011-01       Impact factor: 2.089

Review 3.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

4.  Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.

Authors:  K Yamaguchi; K Motegi; Y Iwakura; Y Endo
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 5.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

6.  A novel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Cl- extrusion in osteoclasts.

Authors:  Kimiko Ohgi; Hiroshi Kajiya; Fujio Okamoto; Yoshiyuki Nagaoka; Tokuya Onitsuka; Atsushi Nagai; Ryuji Sakagami; Koji Okabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-06       Impact factor: 3.000

Review 7.  Bisphosphonate mechanism of action.

Authors:  Alfred A Reszka; Gideon A Rodan
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

Review 8.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

9.  Squalene synthase as a target for Chagas disease therapeutics.

Authors:  Na Shang; Qian Li; Tzu-Ping Ko; Hsiu-Chien Chan; Jikun Li; Yingying Zheng; Chun-Hsiang Huang; Feifei Ren; Chun-Chi Chen; Zhen Zhu; Melina Galizzi; Zhu-Hong Li; Carlos A Rodrigues-Poveda; Dolores Gonzalez-Pacanowska; Phercyles Veiga-Santos; Tecia Maria Ulisses de Carvalho; Wanderley de Souza; Julio A Urbina; Andrew H-J Wang; Roberto Docampo; Kai Li; Yi-Liang Liu; Eric Oldfield; Rey-Ting Guo
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.